Skip to main content
. Author manuscript; available in PMC: 2013 Aug 5.
Published in final edited form as: Mol Pharm. 2012 Apr 6;9(5):1118–1125. doi: 10.1021/mp2003835

Figure 2.

Figure 2

Enhanced OVA-specific cytotoxic activity by lip{LLO,OVA,ISS}. Mice were immunized subcutaneously at week zero and boosted at week two with the same formulations containing OVA (8 μg). OVA-specific CTL activity was monitored using 51Cr release assay. Each point represents the mean specific lysis of individual splenocytes cultures (n=10) for each group. Standard deviation is shown for liposome groups. * Statistical significance was observed when comparing lip{LLO,OVA} and lip{LLO,OVA,ISS} at all effector:target ratios, p=0.006, p=0.02, p=0.03 at 40:1, 10:1 and 2.5:1, respectively.